TuHURA Biosciences, Inc./NV (HURA) FY2024 10-K Annual Report
TuHURA Biosciences, Inc./NV (HURA) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 31, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
TuHURA Biosciences, Inc./NV FY2024 10-K Analysis
Business Overview
- • Core business: Clinical-stage immuno-oncology focused on innate immune agonists and tumor microenvironment modulators to overcome resistance to checkpoint inhibitors
- • New emphasis: Acquisition of Kineta, Inc. to incorporate anti-VISTA antibody checkpoint inhibitor targeting acquired resistance
- • Strategic shift: Reverse merger and rebranding to TuHURA Biosciences; expansion into bi-functional ADCs/APCs targeting Delta Opioid Receptor on MDSCs
- • Quantitative metric: Planned Phase 3 trial for IFx-2.0 targeting Merkel cell carcinoma with FDA accelerated approval pathway, Phase 3 start possible Q2 2025
- • Noteworthy fact: Unique bi-specific antibody-peptide conjugates using Delta Opioid Receptor technology represent a novel approach to modulate tumor microenvironment immunosuppression
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided text
- • No segment performance data available
- • No information on cash flow, buybacks, dividends, or capital expenditures
- • Management highlights risk and uncertainty in business environment with no specific outlook or guidance
- • Forward-looking statements qualified with caution, no numerical forecasts provided
Risk Factors
- • FDA partial clinical hold on Phase 3 IFx-2.0 trial to be lifted by Q2 2025 per agreement, critical to initiation of pivotal registration study
- • Direct exposure to regulatory milestones in Kintara Merger earnout: enrollment of 10 metastatic breast cancer patients plus 8 weeks follow-up by Dec 31, 2025
- • Heavy dependence on third-party CROs and manufacturers for clinical trials and product supply for IFx-2.0 and KVA12123 antibody programs
- • Competitive threat from established checkpoint inhibitor Keytruda® (Merck), partnered product in Phase 3 trial, and emerging anti-VISTA asset KVA12123 via Kineta acquisition
- • High leverage from $31.3M convertible notes at 20% interest converted into equity in 2024, with only $12.7M cash on hand at year-end, raising near-term liquidity risk
TuHURA Biosciences, Inc./NV FY2024 Key Financial MetricsXBRL
Revenue
$0
Net Income
-$22M
▲ +26.0% YoY
ROE
-148.6%
▼ -202937bp YoY
Total Assets
$20M
▲ +357.8% YoY
EPS (Diluted)
$-1.21
▲ +51.0% YoY
Operating Cash Flow
-$15M
▼ -23.2% YoY
Source: XBRL data from TuHURA Biosciences, Inc./NV FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TuHURA Biosciences, Inc./NV
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.